The Psychedelics and Wellness Study (PAWS), is an anonymous online survey investigating the interrelationship between psychedelics and wellness. The study population is adults ages 18 and older that have taken a psychedelic at least once. The maximum sample size is 5,000 survey respondents. It is expected that this anonymous online survey will support the hypothesis that there is a robust interrelationship between past psychedelic use and its impact on wellness.
Country United States of America
Visit trial
Trial Details
Trial Number
Sponsors & Collaborators
Yale UniversityThe Yale Psychedelic Science Group was established in 2016.
Papers
Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental StatesThis cross-sectional online survey (n=228) examined the effects of psychedelic use on healthcare providers who treat psychiatric disorders with medications. The study found that psychedelic use was associated with improvements in depression, anxiety, well-being, and resilience, and a decrease in reported suicidality. A factor analysis indicated that a combination of mystical, interpersonal, and personal experiences predicted these improvements. The preferred psychedelic agent did not influence outcomes, and frequency of use showed varied effect sizes. While 13.2% (n=30) reported at least one harm from psychedelic use, the results suggest potential benefits for healthcare providers, consistent with findings from other studies on the general population.
Measures Used
Patient Health Questionnaire for DepressionThe PHQ-9 is the module of the Patient Health Questionnaire focusing on major depressive disorder (MDD). It is a 3-page questionnaire that can be entirely self-administered by the patient, after which it is checked by a medical professional. The PHQ-9 consists of 9 items. If 5 or more criteria have been met, the patient is diagnosed with depression.